459 related articles for article (PubMed ID: 19112815)
1. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
2. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
3. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
4. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).
Kim JH; Psevdos G; Gonzalez E; Singh S; Kilayko MC; Sharp V
Infection; 2013 Apr; 41(2):545-51. PubMed ID: 23264096
[TBL] [Abstract][Full Text] [Related]
5. [Sex specific mortality in HIV/AIDS patients receiving antiretroviral therapy and risk factors in Xinjiang Uygur autonomous region].
Ni M; Chen X; Ma Y; Hu X
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Sep; 36(9):971-5. PubMed ID: 26814865
[TBL] [Abstract][Full Text] [Related]
6. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005.
Yang CH; Huang YF; Hsiao CF; Yeh YL; Liou HR; Hung CC; Yang SY
HIV Med; 2008 Aug; 9(7):535-43. PubMed ID: 18554309
[TBL] [Abstract][Full Text] [Related]
7. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.
Etard JF; Ndiaye I; Thierry-Mieg M; Guèye NF; Guèye PM; Lanièce I; Dieng AB; Diouf A; Laurent C; Mboup S; Sow PS; Delaporte E
AIDS; 2006 May; 20(8):1181-9. PubMed ID: 16691070
[TBL] [Abstract][Full Text] [Related]
8. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
10. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
Krentz HB; Kliewer G; Gill MJ
HIV Med; 2005 Mar; 6(2):99-106. PubMed ID: 15807715
[TBL] [Abstract][Full Text] [Related]
11. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
12. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
Lewden C; Salmon D; Morlat P; Bévilacqua S; Jougla E; Bonnet F; Héripret L; Costagliola D; May T; Chêne G;
Int J Epidemiol; 2005 Feb; 34(1):121-30. PubMed ID: 15561752
[TBL] [Abstract][Full Text] [Related]
13. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease.
Anastos K; Barrón Y; Miotti P; Weiser B; Young M; Hessol N; Greenblatt RM; Cohen M; Augenbraun M; Levine A; Muñoz A;
Arch Intern Med; 2002 Sep; 162(17):1973-80. PubMed ID: 12230420
[TBL] [Abstract][Full Text] [Related]
14. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
15. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.
Smit C; Geskus R; Walker S; Sabin C; Coutinho R; Porter K; Prins M;
AIDS; 2006 Mar; 20(5):741-9. PubMed ID: 16514305
[TBL] [Abstract][Full Text] [Related]
16. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Yephthomi T; Pradeep A; Saghayam S; Flanigan T; Mayer KH; Solomon S
Int J Infect Dis; 2010 Feb; 14(2):e127-31. PubMed ID: 19632872
[TBL] [Abstract][Full Text] [Related]
18. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
[TBL] [Abstract][Full Text] [Related]
19. Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.
Taiwo BO; Li X; Palella F; Jacobson LP; Margolick JB; Detels R; Rinaldo CR; Phair JP
HIV Med; 2009 Nov; 10(10):657-60. PubMed ID: 19601997
[TBL] [Abstract][Full Text] [Related]
20. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
